Investigations
Replimune Group, Inc.
Overview
Overview
- Deadline:
- Upcoming
| Company Name: | Company Name: Replimune Group, Inc. |
| Stock Symbol: | Stock Symbol: REPL |
Replimune Group, Inc. (NASDAQ: REPL): Replimune Group, Inc. (“Replimune” or the “Company”) is being investigated for violations of the federal securities laws in connection with potential false and misleading statements made to investors and a subsequent significant price decline in the stock.
If you incurred losses on your investments in Replimune, you are encouraged to submit your information.
Why Is Replimune Being Investigated?
Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. Replimune’s lead product candidate is RP1, a treatment for melanoma. On June 6, 2024, the Company announced positive top line results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with the immunotherapy drug nivolumab. On November 21, 2024, Replimune announced that it had submitted a biologics license application (“BLA”) to the FDA for RP1 on the strength of the results of the IGNYTE Phase 1/2 trial.
During the relevant period, the Company repeatedly touted the results of the IGNYTE Phase 1/2 trial.
In truth, the IGNYTE Phase 1/2 trial design was not adequate to produce reliable results.
The Stock Declines as the Truth Is Revealed
On July 22, 2025, Replimune announced that it received a Complete Response Letter from the FDA regarding the BLA for RP1. According to the Company, “[t]he FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” More specifically, “the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.” On this news, the price of Replimune stock fell more than 75% on July 22, 2025.
Contact Us
If you incurred losses on your investments in Replimune, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
If you incurred losses on your investments in Replimune, you are encouraged to submit your information.
Why Is Replimune Being Investigated?
Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. Replimune’s lead product candidate is RP1, a treatment for melanoma. On June 6, 2024, the Company announced positive top line results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with the immunotherapy drug nivolumab. On November 21, 2024, Replimune announced that it had submitted a biologics license application (“BLA”) to the FDA for RP1 on the strength of the results of the IGNYTE Phase 1/2 trial.
During the relevant period, the Company repeatedly touted the results of the IGNYTE Phase 1/2 trial.
In truth, the IGNYTE Phase 1/2 trial design was not adequate to produce reliable results.
The Stock Declines as the Truth Is Revealed
On July 22, 2025, Replimune announced that it received a Complete Response Letter from the FDA regarding the BLA for RP1. According to the Company, “[t]he FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” More specifically, “the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.” On this news, the price of Replimune stock fell more than 75% on July 22, 2025.
Contact Us
If you incurred losses on your investments in Replimune, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.